Moderna’s COVID-19 vaccine brought in nearly US$7 billion in the final quarter of 2021, and the drugmaker says it has signed purchase agreements for another US$19 billion in sales this year.
The vaccine maker’s COVID-19 shots, which are now available in more than 70 countries, totaled US$17.7 billion in sales last year, their first full year on the market.
Moderna’s COVID-19 vaccine is the only product the drugmaker has on the market.
Late last month, U.S. regulators gave full approval to the vaccine, which is now being marketed under the name Spikevax.
But the company is still waiting for U.S. regulators to authorize the vaccine’s use in 12- to 17-year olds, even though several other countries have authorized that expanded use.
Regulators are studying the rare risk of a heart inflammation that has shown up in some people who have received the shots.
More than 75 million people have become fully vaccinated with Moderna’s shot in the United States since its emergency authorization over a year ago, according to the Centers for Disease Control and Prevention.
Another 40 million have received booster doses.
In the recently completed fourth quarter, Moderna earned US$4.87 billion on US$7.21 billion in revenue, while earnings per share came to US$11.29.
Analysts expect, on average, earnings of US$9.96 per share on US$6.8 billion in revenue, according to FactSet.
For the full year, Moderna earned US$12.2 billion, compared to a net loss of US$747 million in 2020.
For 2022, the Cambridge, Massachusetts company said in November it expects revenue between US$17 billion and US$22 billion.
Analysts forecast US$21.5 billion in revenue.
The company said Thursday that its purchase agreements for the new year include an additional US$3 billion in options for any potential updated vaccine boosters.
Shares of Moderna Inc. tumbled more than 6 per cent in premarket trading. Broader U.S. trading indexes dropped more than 2 per cent after Russia launched a military attack on Ukraine.
